Please assess the completion status of the following clinical trial:

Trial Title: Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary endometrial carcinoma meeting 1 of the following criteria:~  * Stage III or IV disease according to FIGO staging criteria~ * Recurrent disease that is considered incurable~* Measurable disease~  * A lesion within a previously irradiated field is acceptable as measurable disease only if there has been clear progression since completion of radiotherapy~PATIENT CHARACTERISTICS:~* GOG performance status 0-2~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL~* Creatinine \< 2.5 mg/dL OR creatinine clearance ≥ 60 mL/min~* ALT and AST ≤ 1.5 times upper limit of normal (ULN) (3 times ULN in the presence of liver metastases)~* Alkaline phosphatase ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases)~* Total bilirubin ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases)~* Not pregnant or nursing~* Left ventricular ejection fraction (LVEF) ≥ 50% by MUGA scan or ECHO~* No history of severe hypersensitivity reaction to doxorubicin hydrochloride liposome~* No other invasive malignancy (i.e., breast cancer) within the past 5 years except nonmelanoma skin cancer~* No cardiac disease, including any of the following:~  * Myocardial infarction within the past 6 months~ * NYHA class II-IV heart failure~ * Uncontrolled angina~ * Severe uncontrolled ventricular arrhythmias~ * Clinically significant pericardial disease~ * Acute ischemic or active conduction system abnormalities by ECHO~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy~* No prior cancer therapy that would contraindicate study treatment~* No concurrent investigational agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxorubicin and carboplatin (Type: EXPERIMENTAL): Patients receive doxorubicin hydrochloride liposome IV over 1 hour on day 1 and carboplatin IV over 30 minutes on day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).